RCS - Synairgen plc - Synairgen announces partnership with Ashfield

SynairgenAnnouncement

06/01/2022 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220106:nRSF6659Xa&default-theme=true

RNS Number : 6659X  Synairgen plc  06 January 2022

Press Release

 

 

Synairgen plc

('Synairgen' or the 'Company')

 

Synairgen announces global strategic partnership with Ashfield Engage

 

Southampton, UK - 6 January 2022: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001 (inhaled interferon-beta or IFN-beta) for the
treatment of COVID-19 as potentially the first host-targeted, broad-spectrum
antiviral treatment delivered directly into the lungs, today announces a
partnership with global experts in strategic engagement and commercialisation,
Ashfield Engage.

Leveraging its COVID-19 experience, Ashfield Engage is supporting Synairgen as
it builds its commercialisation infrastructure for the needs of SNG001,
initially in the US, pending completion of pivotal trials and regulatory
authorisations. This will include the recruitment of dedicated medical
affairs, patient services, commercial and market access teams.

SNG001 is an investigational inhaled formulation of the naturally occurring
antiviral protein IFN-beta for potential use in patients hospitalised with
COVID-19. The SARS-CoV-2 virus supresses local production of IFN-beta prevents
induction of anti-viral responses by infected cells.

"There remains an urgent need for new therapies to treat hospitalised COVID-19
patients in order to prevent disease progression, accelerate hospital
discharge and enable patients to quickly resume their usual activities," said
Richard Hennings, Chief Commercial Officer of Synairgen. "We are excited to be
working with Ashfield Engage given their relevant COVID-19 experience and are
confident they understand our needs and values as we build the optimal team."

In November 2021, Synairgen announced that it had completed enrolment of 610
patients in its Phase 3 SPRINTER trial (SG018) and expects top-line data early
this year. SNG001 has also recently graduated to the Phase 3 part of the US
National Institute of Health's ACTIV-2 trial.

Greg Flynn, Global President of Ashfield Engage, said: "It is a privilege to
support Synairgen in bringing this innovative potential treatment to COVID-19
patients. Having initially collaborated with Synairgen regarding patient
support, we have together developed a truly consultative approach - taking the
time to fully understand patient needs and providing solutions in both
hospital and home settings.

"We're grateful that our collaboration has now evolved into a significantly
wider partnership which will see us recruiting experts to support delivery of
this novel nebulised antiviral to patients, providing MSLs to educate on the
SNG001 treatment, and establishing medical information services to respond to
patient enquiries."

SNG001 has been granted Fast Track status from the US Food and Drug
Administration (FDA) and the Phase 3 SPRINTER trial was classified as an
Urgent Public Health study by the UK's National Institute for Health Research
(NIHR).

 

No financial terms have been disclosed regarding the partnership with Ashfield
Engage.

 

For further enquiries, please contact:

 

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Chief Financial Officer

Brooke Clarke, Head of Communications

Brooke.Clarke@synairgen.com (mailto:Brooke.Clarke@synairgen.com)

Tel: + 44 (0) 23 8051 2800

 

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

 

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

 

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone

synairgen@consilium-comms.com (mailto:synairgen@consilium-comms.com)

Tel: +44 (0) 20 3709 5700

 

MKC STRATEGIES, LLC (US Media Relations)

Mary Conway

MConway@MKCStrategies.com (mailto:MConway@MKCStrategies.com)

Tel: +1 516-606-6545

 

 

Notes for Editors

 

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery,
development and commercialisation. The Company's primary focus is developing
SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially
the first host-targeted, broad-spectrum antiviral treatment delivered directly
into the lungs. SNG001 has been granted Fast Track status from the US Food and
Drug Administration (FDA) and the Phase 3 SPRINTER trial was deemed an Urgent
Public Health study by the UK's National Institute for Health Research (NIHR).
Synairgen's Phase 3 clinical programme is currently evaluating SNG001 in
patients across 17 countries. In a Phase 2 trial in hospitalised COVID-19
patients, SNG001 demonstrated a greater than two-fold chance of recovery to
'no limitation of activities' versus placebo.(1)

 

Founded by University of Southampton Professors Sir Stephen Holgate, Donna
Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG).
For more information about Synairgen, please see www.synairgen.com
(http://www.synairgen.com) .

 

(1)https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
(https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext)
 

 

About Ashfield Engage

Ashfield Engage is an expert, global partner in customer strategy and
execution. Ashfield Engage helps clients to connect with all healthcare
audiences to ensure people get knowledge, support and medicines when and where
they need them. As experts in strategic engagement, Ashfield Engage creates
personalised, impactful experiences for all healthcare audiences, across all
channels. Every programme is underpinned by human connections, omnichannel
engagement and adaptive analytics.

Ashfield Engage has over 20 years' experience with a team of over 5,000
employees, delivering services in more than 50 countries. Offering services
across Medical Affairs, Commercial, Patient Solutions and Event Experiences,
Ashfield Engage helps its clients to engage with their stakeholders across the
whole commercialisation journey.

For more information, visit www.ashfieldengage.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAFFKEANAEFA